Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils - 08/09/11
Abstract |
Background: Eosinophils are important effector cells in asthma pathogenesis, and an understanding of the mechanisms involved in eosinophil apoptosis induction might thus be relevant to the resolution of asthmatic inflammation. Objective: Our aim was to determine the role of the common leukocyte antigen CD45 and the isoforms CD45RA, CD45RB, and CD45RO in human eosinophil apoptosis induction. Methods: Immmunostaining and flow cytometry were used to assess CD45 and CD45 isoform expression by eosinophils purified with use of density gradients and immunomagnetic negative selection. Apoptosis induction was measured by binding of fluorescein isothiocyanate–labeled annexin V to eosinophils cultured for 20 hours alone or with saturating quantities of mAb against CD45, CD45RA, CD45RB, CD45RO, CD9, CD11b, and isotype-matched controls in the presence or absence of GM-CSF. Results: Freshly isolated eosinophils had high expression of CD45 and CD45RO, modest expression of CD45RB, and low expression of CD45RA. Eosinophils cultured alone for 20 hours were found to be approximately 20% to 25% apoptotic. Incubation with mAb against CD45, CD45RA, and CD45RB resulted in significant (P < .005) enhancement (>100%) of their constitutive rate of apoptosis. Incubation with CD45RO, CD11b, CD9 mAb, or isotype controls had no significant effect on the rate of eosinophil constitutive apoptosis. The addition of GM-CSF inhibited eosinophil apoptosis but did not prevent CD45, CD45RA, or CD45RB mAb-dependent apoptosis induction. Conclusion: These data indicate that ligation of CD45, CD45RA, or CD45RB represents a novel pathway for the induction of apoptosis in human eosinophils. (J Allergy Clin Immunol 1999;104:1244-50.)
Le texte complet de cet article est disponible en PDF.Keywords : Eosinophils, apoptosis, CD45, allergy, asthma, cell surface molecules
Abbreviations : FITC:, PCD:, PI:, PTPase:
Plan
![]() | Supported by the Wellcome Trust, United Kingdom (grant No. 044988/2/95/2). |
![]() ![]() | Reprint requests: Garry M. Walsh, PhD, Department of Medicine and Therapeutics, IMS Building, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom. |
![]() | 0091-6749/99 $8.00 + 0 1/1/102694 |
Vol 104 - N° 6
P. 1244-1250 - décembre 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?